• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预防的成本。

The costs of prevention.

作者信息

Weinstein M C

机构信息

Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115.

出版信息

J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S89-92. doi: 10.1007/BF02600850.

DOI:10.1007/BF02600850
PMID:2231073
Abstract

A prevention program is cost-effective if it yields more health benefits than do alternative uses of health care resources. Some prevention programs meet this standard: either they actually save more health care resources than they utilize, or their net costs per healthy year of life gained are lower than those of alternatives such as curative or palliative medicine. Other prevention programs, however, are less cost-effective than are medical treatments for the same disease. One lesson for public policy is that generalizations about the cost-effectiveness of "prevention" are unwise. Another lesson is that prevention programs should not be subjected to a higher standard than other health programs: they should not be expected to save money, but they should be expected to yield improved health at a reasonable price.

摘要

如果一个预防项目产生的健康效益超过医疗保健资源的其他用途,那么它就是具有成本效益的。一些预防项目符合这一标准:要么它们实际节省的医疗保健资源多于其使用的资源,要么其每获得一个健康生命年的净成本低于诸如治疗或姑息治疗等替代方案。然而,其他预防项目的成本效益低于针对同一种疾病的医疗治疗。公共政策可以吸取的一个教训是,对“预防”的成本效益进行一概而论是不明智的。另一个教训是,预防项目不应受到比其他健康项目更高的标准要求:不应期望它们省钱,但应期望它们以合理的价格带来健康改善。

相似文献

1
The costs of prevention.预防的成本。
J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S89-92. doi: 10.1007/BF02600850.
2
Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?利用成本效益/成本效益分析来分配卫生资源:预防的公平竞争环境?
Am J Prev Med. 1997 Jan-Feb;13(1):18-25.
3
Assessing prevention effectiveness using data to drive program decisions.利用数据评估预防效果,以推动项目决策。
Public Health Rep. 1994 Mar-Apr;109(2):187-94.
4
The economics of prevention.
Health Policy. 1984;4(2):85-100. doi: 10.1016/0168-8510(84)90001-0.
5
A cost evaluation of the Georgia Stroke and Heart Attack Prevention Program.佐治亚州中风与心脏病发作预防项目的成本评估。
Prev Chronic Dis. 2006 Jan;3(1):A12. Epub 2005 Dec 15.
6
The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants.移民肠道寄生虫治疗策略的成本效益
N Engl J Med. 1999 Mar 11;340(10):773-9. doi: 10.1056/NEJM199903113401006.
7
Assessing the effectiveness of disease and injury prevention programs: costs and consequences.评估疾病与伤害预防项目的有效性:成本与后果。
MMWR Recomm Rep. 1995 Aug 18;44(RR-10):1-10.
8
What works, and what remains to be done, in HIV prevention in the United States.在美国,哪些预防艾滋病病毒的措施有效,哪些仍有待开展。
Annu Rev Public Health. 2006;27:261-75. doi: 10.1146/annurev.publhealth.26.021304.144454.
9
The economics of prevention: does it save money?预防的经济学:它能省钱吗?
Tenn Med. 2004 Nov;97(11):495-6, 498.
10
The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.总统2007财年在美国扩大人类免疫缺陷病毒咨询与检测的倡议:对其覆盖范围、影响及成本效益的情景分析
J Public Health Manag Pract. 2007 May-Jun;13(3):239-43. doi: 10.1097/01.PHH.0000267681.00659.e5.

引用本文的文献

1
What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?30 年来,1 型糖尿病患者的血糖控制良好与不佳,在临床、生活质量和成本方面会有什么后果?
J Diabetes Complications. 2018 Oct;32(10):911-915. doi: 10.1016/j.jdiacomp.2018.05.007. Epub 2018 Jun 12.
2
The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).1 型糖尿病实现卓越血糖控制的替代策略的 30 年成本效益:基于糖尿病控制和并发症试验/糖尿病干预和并发症的流行病学(DCCT/EDIC)结果的经济模拟。
J Diabetes Complications. 2018 Oct;32(10):934-939. doi: 10.1016/j.jdiacomp.2018.06.005. Epub 2018 Jun 12.
3

本文引用的文献

1
Cost-effectiveness of coronary artery bypass surgery.冠状动脉搭桥手术的成本效益
Circulation. 1982 Nov;66(5 Pt 2):III56-66.
2
A cost-effectiveness analysis of exercise as a health promotion activity.作为一项健康促进活动的运动的成本效益分析。
Am J Public Health. 1988 Nov;78(11):1417-21. doi: 10.2105/ajph.78.11.1417.
3
Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.急性心肌梗死后长期使用β-肾上腺素能拮抗剂进行常规治疗的成本与效果
Treating cutaneous aging with patented technologies.采用专利技术治疗皮肤老化。
J Biosci. 2015 Jun;40(2):209-16. doi: 10.1007/s12038-015-9522-8.
4
Primordial prevention, developing countries and the epidemiological transition: thirty years later.原始预防、发展中国家与流行病学转变:三十年后
Wien Klin Wochenschr. 2009;121(5-6):168-72. doi: 10.1007/s00508-008-1110-6.
5
Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.法国曲伏前列素与拉坦前列素单药治疗青光眼的成本效益评估。
Clin Drug Investig. 2008;28(3):183-98. doi: 10.2165/00044011-200828030-00005.
6
The financial implications of availability and quality of a usual source of care for children with special health care needs.为有特殊医疗需求的儿童提供常规医疗服务的可及性和质量所产生的财务影响。
Matern Child Health J. 2008 Mar;12(2):243-59. doi: 10.1007/s10995-007-0233-0. Epub 2007 Jun 8.
7
Cost-effectiveness of new tests to diagnose and treat coronary heart disease.用于诊断和治疗冠心病的新检测方法的成本效益。
Curr Treat Options Cardiovasc Med. 2005 Aug;7(4):273-86. doi: 10.1007/s11936-005-0038-7.
8
Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults.免疫预防在预防成人复发性感染性鼻炎中的成本效益
Pharmacoeconomics. 1998 Sep;14(3):313-22. doi: 10.2165/00019053-199814030-00007.
9
Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections.复发性耳鼻喉感染患儿免疫预防的经济学评估
Pharmacoeconomics. 1994 Nov;6(5):464-77. doi: 10.2165/00019053-199406050-00008.
N Engl J Med. 1988 Jul 21;319(3):152-7. doi: 10.1056/NEJM198807213190306.
4
Cost-effectiveness of interventions to prevent or treat coronary heart disease.预防或治疗冠心病干预措施的成本效益
Annu Rev Public Health. 1985;6:41-63. doi: 10.1146/annurev.pu.06.050185.000353.
5
Foundations of cost-effectiveness analysis for health and medical practices.健康与医疗实践的成本效益分析基础
N Engl J Med. 1977 Mar 31;296(13):716-21. doi: 10.1056/NEJM197703312961304.